Comparing a fecal immunochemical test and circulating tumor DNA blood test for colorectal cancer screening adherence
Journal of Gastroenterology and Hepatology · 2024
DOI: 10.1111/jgh.16531 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Geraldine Laven-Law und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Circulating Tumor DNA, Early Detection of Cancer, Occult Blood. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Council SA Beat Cancer Research Project Grant, National Health and Medical Research Council Australia Project Grant.
Abstract (Originalsprache)
Background and Aim Colorectal cancer (CRC) screening programs are most effective at reducing disease incidence and mortality through sustained screening participation. A novel blood test modality is being explored for CRC screening, but it is unclear whether it will provide sustained screening participation. This study aimed to investigate whether a circulating tumor DNA (ctDNA) blood test improved CRC screening re‐participation when compared with a fecal immunochemical test (FIT) and to define the predictors of sustained CRC screening in an Australian population.
Methods
South Australians who initially participated in CRC screening using a ctDNA blood test ( n = 36) or FIT ( n = 547) were offered the same CRC screening test approximately 2 years later through an extended phase of a randomized controlled trial. Surveys collected demographic, psychosocial, and clinical information. Predictors of CRC screening re‐participation were explored using chi‐square, Wilcoxon tests, and logistic regression.
Results
Participants offered a second ctDNA blood test were equally likely to re‐participate in CRC screening as those who completed a FIT in the first round and who were offered the same test (61% vs 66% re‐participation respectively, P = 0.6). CRC fatalism, health activation, and self‐efficacy were associated with repeated screening participation. Test awareness was predictive of repeated FIT‐based CRC screening.
Conclusions
Targeted interventions to improve CRC screening awareness and increase patient health activation may improve CRC screening adherence. A ctDNA blood test may be a suitable CRC screening option to maintain CRC screening adherence in people who do not participate in screening with FIT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia, Australia.
- Department of Gastroenterology and Hepatology, Flinders Medical Centre, Southern Adelaide Local Health Network, Adelaide, South Australia, Australia.
- Centre for Health Economics, Monash University, Caulfield East, Victoria, Australia.
- Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.
ORCID-Profile: Geraldine Laven-Law, Erin L Symonds, Jean M Winter, Gang Chen, Ingrid H Flight, Donna Hughes-Barton, Carlene J Wilson, Graeme P Young
Förderung
- Cancer Council SA Beat Cancer Research Project Grant
- National Health and Medical Research Council Australia Project Grant
Zitieren
APA
Laven-Law, G., Symonds, E. L., Winter, J. M., Chen, G., Flight, I. H., Hughes-Barton, D., Wilson, C. J., & Young, G. P. (2024). Comparing a fecal immunochemical test and circulating tumor DNA blood test for colorectal cancer screening adherence. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16531
Vancouver
Laven-Law G, Symonds EL, Winter JM, Chen G, Flight IH, Hughes-Barton D, et al. Comparing a fecal immunochemical test and circulating tumor DNA blood test for colorectal cancer screening adherence. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16531
BibTeX
@article{LavenLaw2024,
author = {Laven-Law, Geraldine and Symonds, Erin L and Winter, Jean M and Chen, Gang and Flight, Ingrid H and Hughes-Barton, Donna and Wilson, Carlene J and Young, Graeme P},
title = {Comparing a fecal immunochemical test and circulating tumor DNA blood test for colorectal cancer screening adherence},
journal = {Journal of Gastroenterology and Hepatology},
year = {2024},
doi = {10.1111/jgh.16531}
}
EUVIMED